Acute Leukemia of Ambiguous Lineage

Oncology·MeSH: Leukemia, Biphenotypic, Acute

24 drugs in development·6 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(13)

Drug	Company
Asparaginase Erwinia chrysanthemi	Cosmos Health Inc. (COSM)
Blinatumomab	Cosmos Health Inc. (COSM)
Calaspargase Pegol	Cosmos Health Inc. (COSM)
Cytarabine	Cosmos Health Inc. (COSM)
Daunorubicin	Cosmos Health Inc. (COSM)
leucovorin	GH Research PLC (GHRS)
Leucovorin	Cosmos Health Inc. (COSM)
Levoleucovorin	Cosmos Health Inc. (COSM)
Levoleucovorin	Assertio Holdings, Inc. (ASRT)
Mercaptopurine	Cosmos Health Inc. (COSM)
Thioguanine	Cosmos Health Inc. (COSM)
vincristine	GH Research PLC (GHRS)
Vincristine	Cosmos Health Inc. (COSM)

Phase 2(8)

Drug	Company
Levoleucovorin	Filana Therapeutics Inc. (FLNA)
Levoleucovorin	AXIM BIOTECHNOLOGIES, INC. (AXIM)
revumenib	GH Research PLC (GHRS)
Therapeutic Hydrocortisone	Cosmos Health Inc. (COSM)
Therapeutic Hydrocortisone	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Venetoclax	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Venetoclax	Cosmos Health Inc. (COSM)
Venetoclax	Assertio Holdings, Inc. (ASRT)

Phase 1(1)

Drug	Company
Filgrastim	AbbVie Inc. (ABBV)

Phase 2/Phase 3(2)

Drug	Company
blinatumomab	GH Research PLC (GHRS)
calaspargase pegol	GH Research PLC (GHRS)

BioSniper tracks 24 drugs in development for Acute Leukemia of Ambiguous Lineage across 6 companies.

There are 7 clinical trials targeting Acute Leukemia of Ambiguous Lineage tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.